Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study

BACKGROUND: Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. Currently Dengvaxia, the first dengue vaccine licensed in 20 countries, was recommended for DENV seropositive individuals aged 9–45 years. Studying dengue seroprevalence can improve our understanding of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Jih-Jin, Tsai, Ching-Yi, Lin, Ping-Chang, Chen, Chun-Hong, Tsai, Wen-Yang, Dai, Yu-Ching, Lin, Yen-Chia, Pedroso, Celia, Brites, Carlos, Wang, Wei-Kung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165301/
https://www.ncbi.nlm.nih.gov/pubmed/37158835
http://dx.doi.org/10.1186/s12879-023-08307-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165301/
https://www.ncbi.nlm.nih.gov/pubmed/37158835
http://dx.doi.org/10.1186/s12879-023-08307-8

Ejemplares similares